Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis

Cornea

Volumn 30, Issue 12, 2011, Pages 1398-1405

  Maier, Anna Karina B ^a   Ozlügedik, Sevil ^b   Rottler, Jessica ^c   Heussen, Florian M A ^a   Klamann, Matthias K J ^a   Huber, Klaudia K ^b   Joussen, Antonia M ^a   Winterhalter, Sibylle ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

Author keywords

corneal vascularization; cyclosporine A; high risk keratoplasty; HSV keratitis; mycophenolate mofetil

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; EYE DROPS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; STEROID;

ADULT; AGED; APPETITE DISORDER; ARTICLE; CORNEA VASCULARIZATION; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KERATOPLASTY; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; STOMACH DISEASE; SURGICAL RISK; SYSTEMIC THERAPY; VISUAL ACUITY; WEAKNESS;

ACYCLOVIR; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATITIS, HERPETIC; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE CARE; RECURRENCE; RETROSPECTIVE STUDIES; VISUAL ACUITY; YOUNG ADULT;

EID: 81355160323     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31821e65b3     Document Type: Article

References (43)

1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
2. Mayer K, Reinhard T, Reis A, et al. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol. 2003;241:1051-1054.
3. Epstein RJ, Seedor JA, Dreizen NG, et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology. 1987;94:935-944.
4. Kersten A, Sundmacher R, Reinhard T. Postoperative complications of penetrating keratoplasty in herpes infected eyes. Differential diagnosis, therapy and prognostic significance [in German]. Ophthalmologe. 1997; 94:889-896.
5. Barney NP, Foster CS. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 1994; 13:232-236.
6. Tambasco FP, Cohen EJ, Nguyen LH, et al. Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol. 1999;117:445-449.
7. Jansen AF, Rijneveld WJ, Remeijer L, et al. Five-year follow-up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. Cornea. 2009;28:843-845.
8. Shtein RM, Garcia DD, Musch DC, et al. Herpes simplex virus keratitis: histopathologic inflammation and corneal allograft rejection. Ophthalmology. 2009;116:1301-1305.
9. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol. 2009;54:226-234.
10. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol. 1989;107:506-510.
11. Hill JC. The use of systemic cyclosporin A in human corneal transplantation: a preliminary report. Doc Ophthalmol. 1986;62:337-344.
12. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology. 1994;101:128-133.
13. Hill JC. Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond). 1995;9(pt 4):422-428.
14. Reinhard T, Sundmacher R, Godehardt E, et al. Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor [in German]. Ophthalmologe. 1997;94:496-500.
15. Poon AC, Forbes JE, Dart JK, et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol. 2001; 85:1464-1469.
16. Volker-Dieben HJ, Claas FH, Schreuder GM, et al. Beneficial effect of HLA-DR matching on the survival of corneal allografts. Transplantation. 2000;70:640-648.
17. Inoue K, Kimura C, Amano S, et al. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol. 2001;45:378-382.
18. Reinhard T, Reis A, Kutkuhn B, et al. Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study [in German]. Klin Monatsbl Augenheilkd. 1999;215:201-202.
19. Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 2001;239:367-372.
20. Neyts J, De Clercq E. Mycophenolate mofetil strongly potentiates the antiherpesvirus activity of acyclovir. Antiviral Res. 1998;40:53-56.
21. Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol. 1999;83:1268-1271.
22. Reinhard T, Mayweg S, Sokolovska Y, et al. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int. 2005;18:703-708.
23. Spelsberg H, Reinhard T, Henke L, et al. Penetrating limbo-keratoplasty for granular and lattice corneal dystrophy: survival of donor limbal stem cells and intermediate-term clinical results. Ophthalmology. 2004;111: 1528-1533.
24. Joussen AM, Heussen FM, Joeres S, et al. Autologous translocation of the choroid and retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol. 2006;142:17-30.
25. Hill JC. The relative importance of risk factors used to define high-risk keratoplasty. Ger J Ophthalmol. 1996;5:36-41.
26. Halberstadt M, Machens M, Gahlenbek KA, et al. The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin. Br J Ophthalmol. 2002;86:646-652.
27. Garcia DD, Farjo Q, Musch DC, et al. Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 2007; 26:930-934.
28. Reisr A, Reinhard T, Voiculescu A, et al. Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease [in German]. Klin Monatsbl Augenheilkd. 2001;218: 183-186.
29. Hill JC. Immunosuppression in corneal transplantation. Eye (Lond). 1995; 9(pt 2):247-253.
30. Hill JC, Ivey A. Corticosteroids in corneal graft rejection: double versus single pulse therapy. Cornea. 1994;13:383-388.
31. Brik D, Dunkel E, Pavan-Langston D. Herpetic keratitis: persistence of viral particles despite topical and systemic antiviral therapy. Report of two cases and review of the literature. Arch Ophthalmol. 1993;111: 522-527.
32. Gangappa S, Babu JS, Thomas J, et al. Virus-induced immunoinflammatory lesions in the absence of viral antigen recognition. J Immunol. 1998; 161:4289-4300.
33. Thomas J, Rouse BT. Immunopathology of herpetic stromal keratitis: discordance in CD4+ T cell function between euthymic host and reconstituted SCID recipients. J Immunol. 1998;160:3965-3970.
34. Moyes AL, Sugar A, Musch DC, et al. Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol. 1994;112: 601-607.
35. Akova YA, Onat M, Duman S. Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex keratitis. Ocul Immunol Inflamm. 1999;7:51-60.
36. Garcia DD, Shtein RM, Musch DC, et al. Herpes simplex virus keratitis: histopathologic neovascularization and corneal allograft failure. Cornea. 2009;28:963-965.
37. Toma HS, Murina AT, Areaux RG Jr, et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008;23:249-273.
38. Polcicova K, Biswas PS, Banerjee K, et al. Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. Proc Natl Acad Sci U S A. 2005;102:11462-11467.
39. Deshpande S, Zheng M, Lee S, et al. Bystander activation involving T lymphocytes in herpetic stromal keratitis. J Immunol. 2001;167:2902-2910.
40. Yoon KC, Heo H, Kang IS, et al. Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea. 2008;27:454-460.
41. Ficker LA, Kirkness CM, Rice NS, et al. The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology. 1989;96:1587-1596.
42. Foster CS, Barney NP. Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis. Doc Ophthalmol. 1992;80:363-369.
43. Ignatius R, Hoffmann F. Typing for HLA matching. Advantages for keratoplasty [in German]. Ophthalmologe. 2007;104:213-218.